1. Abe, E., Casamenti, F., Giovannelli, L., Scali, C., & Pepeu, G. (1994). Administration of amyloid β-peptides into the medial septum of rats decreases acetylcholine release from hippocampus in vivo. Brain Research, 636(1), 162-164. [DOI:10.1016/0006-8993(94)90193-7] [
DOI:10.1016/0006-8993(94)90193-7]
2. Bassil, N., & Grossberg, G. T. (2017). Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs, 23(2), 293-307. [DOI:10.2165/00023210-200923040-00003] [PMID] [
DOI:10.2165/00023210-200923040-00003]
3. Cacabelos, R. (2007). Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics. Neuropsychiatry Diseases Treatment, 3(3), 303-33. [PMID] [PMCID] [
PMID] [
PMCID]
4. Cetin, F., Dincer, S. (2007). The Effect of Intrahippocampal Beta amyloid (1-42) peptide injection on oxidant and antioxidant status in rat brain. Annals of New York Academy of Sciences, 1100, 510-17. [DOI:10.1196/annals.1395.056] [PMID] [
DOI:10.1196/annals.1395.056]
5. Christensen, R., Marcussen, A. B., Wörtwein, G., Knudsen, G.M., & Aznar, S. (2008). A beta (1-42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT (2A) levels. Experimental Neurology, 210(4), 164-71. [DOI:10.1016/j.expneurol.2007.10.009] [PMID] [
DOI:10.1016/j.expneurol.2007.10.009]
6. Fahnestock, M., Marchese, M., Head, E., Pop, V., Michalski, B., & Milgram, W. N. (2012). BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiology of Aging, 33(3), 546-54. [DOI:10.1016/j.neurobiolaging.2010.03.019] [PMID] [PMCID] [
DOI:10.1016/j.neurobiolaging.2010.03.019]
7. Fellgiebel, A., & Yakushev, I. (2011). Diffusion tensor imaging of the hippocampus in MCI and early Alzheimer's disease. Journal of Alzheimers Disease, 26(Suppl3), 257-62. [DOI:10.3233/JAD-2011-0001] [PMID] [
DOI:10.3233/JAD-2011-0001]
8. Fitzgerald, L. W., & Dokla, C. P. (1989). Morris water task impairment and hypoactivity following cysteamine-induced reductions of somatostatin-like immunoreactivity. Brain Research, 505(2), 246-50. [DOI:10.1016/0006-8993(89)91450-9] [
DOI:10.1016/0006-8993(89)91450-9]
9. Forsyth, D. R., Surmon, D. J., Morgan, R. A., & Wilcock, G. K. (1989). Clinical experience with and side-effects of tacrine hydrochloride in Alzheimer's disease: A pilot study. Age and Ageing, 18(4), 223-29. [DOI:10.1093/ageing/18.4.223] [PMID] [
DOI:10.1093/ageing/18.4.223]
10. Gholamipour-Badie, H., Naderi, N., Khodagholi, F., Shaerzadeh, F., & Motamedi, F. (2013). L-type calcium channel blockade alleviates molecular and reversal spatial learning and memory alterations induced by entorhinal amyloid pathology in rats. Behavioural Brain Research, 237(2), 190-99. [DOI:10.1016/j.bbr.2012.09.045] [PMID] [
DOI:10.1016/j.bbr.2012.09.045]
11. Hosseinzadeh, H., Ramezani, M., & Salmani, G. (2000). Antinociceptive, anti-inflammatory and acute toxicity effect of Zataria multiflora Boiss. extracts in mice and rats. Journal of Ethnopharmacology, 73(3), 379-85. [DOI:10.1016/S0378-8741(00)00238-5] [
DOI:10.1016/S0378-8741(00)00238-5]
12. Jeong, J. H., Jeong, H. R., Jo, Y. N., Kim, H. J., Shin, J. H., & Heo, H. J. (2013). Ameliorating effects of aged garlic extracts against Abeta-induced neurotoxicity and cognitive impairment. BMC Complementary, 13(6), 268. [DOI:10.1186/1472-6882-13-268] [PMID] [PMCID] [
DOI:10.1186/1472-6882-13-268]
13. Jukic, M., Politeo, O., Maksimovic, M., Milos, M., & Milos, M. (2007). In vitro acetylcholinesterase inhibitory properties of thymol, carvacrol and their derivatives thymo quinone and thymo hydroquinone. Phytotherapy Research, 21(2), 259-61. [DOI:10.1002/ptr.2063] [PMID] [
DOI:10.1002/ptr.2063]
14. Li, H., Wu, X., Bai, Y., Hung, Y., He, W., & Dong, Z. (2012). Unilateral lesion of dorsal hippocampus in adult rats impairs contralateral long-term potentiation in vivo and spatial memory in the early postoperative phase. Behavioural Brain Research, 230(3), 428-32. [DOI:10.1016/j.bbr.2012.05.035] [PMID] [
DOI:10.1016/j.bbr.2012.05.035]
15. Lieo, A., Greenberg, S. M., & Growdon, J. H. (2006). Current pharmacotherapy for Alzheimer's disease. Annual Review of Medicine, 57(4), 513–33. [DOI:10.1146/annurev.med.57.121304.131442] [PMID] [
DOI:10.1146/annurev.med.57.121304.131442]
16. Majlesi, N., Choopani, S., Kamalinejad, M., & Azizi, Z. (2012). Amelioration of amyloid β-induced cognitive deficits by Zataria multiflora Boiss. essential oil in a rat model of Alzheimer's disease. CNS Neuroscience & Therapeutics, 18(4), 295-301. [DOI:10.1111/j.1755-5949.2011.00237.x] [PMID] [
DOI:10.1111/j.1755-5949.2011.00237.x]
17. Mimica, N., & Presecki, P. (2009). Side effects of approved anti-dementives. Psychiatry Danub, 21(4), 108-13. [PMID] [
PMID]
18. Miranda, M. D., de Bruin, V. M. S., Vale, M. R., & Viana, G. S. B. (2000). Lipid peroxidation and nitrite plus nitrate levels in brain tissue from patients with Alzheimer's Disease. Gerontology, 46(3), 179-184. [DOI:10.1159/000022156] [PMID] [
DOI:10.1159/000022156]
19. Muller, T. (2007). Rivastigmine in the treatment of patients with Alzheimer's Disease. The American Journal of Pathology, 3(4), 211-8. [DOI:10.2147/nedt.2007.3.2.211] [
DOI:10.2147/nedt.2007.3.2.211]
20. Murer, M. G., Yan, Q., & Raisman-Vozari, R. (2001). Brain-derived neurotrophic factor in the control human brain, and in Alzheimer's Disease and Parkinson's disease. Progress in Neurobiology, 63(4), 71-124. [DOI:10.1016/S0301-0082(00)00014-9] [
DOI:10.1016/S0301-0082(00)00014-9]
21. Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., et al. (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's Disease. Nature Medicine, 15(3), 331-7. [DOI:10.1038/nm.1912] [PMID] [PMCID] [
DOI:10.1038/nm.1912]
22. Parihar, M. S., & Hemnani, T. (2004). Alzheimer's Disease pathogenesis and therapeutic interventions. Journal of Clinical Neuroscience, 11(1), 456-67. [DOI:10.1016/j.jocn.2003.12.007] [PMID] [
DOI:10.1016/j.jocn.2003.12.007]
23. Paxinos, G., & Watson, C. (2007). The rat brain in stereotaxic coordinates. 6th Ed. New York: Academic Press. [PMCID] [
PMCID]
24. Postu, P. A., Noumedem, J. A. K., Cioanca, O., Hancianu, M., Mihasan, M., Ciorpac, M., et al. (2017). Lactuca capensis reverses memory deficits in Aβ1-42-induced an animal model of Alzheimer's Disease. Journal of Cellular and Molecular Medicine, 22(1), 111-22. [DOI:10.1111/jcmm.13299] [
DOI:10.1111/jcmm.13299]
25. Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y., & Prina, A. M. (2015). World Alzheimer Report 2015: The global impact of dementia. An analysis of prevalence, incidence, costs and trends. London: Alzheimer's Disease Association.
26. Ramin, M., Azizi, P., Motamedi, F., Haghparast, A., & Khodagholi, F. (2011). Inhibition of JNK phosphorylation reverses memory deficit induced by β-amyloid (1-42) associated with decrease of apoptotic factors. Behavioural Brain Research, 217(2), 424-31. [DOI:10.1016/j.bbr.2010.11.017] [PMID] [
DOI:10.1016/j.bbr.2010.11.017]
27. Reddy, P. H. (2006). Amyloid precursor protein-mediated free radicals and oxidative damage: Implications for the development and progression of Alzheimer's Disease. Journal of Neurochemistry, 96(1), 1-13. [DOI:10.1111/j.1471-4159.2005.03530.x] [PMID] [
DOI:10.1111/j.1471-4159.2005.03530.x]
28. Sajed, H., Sahebkar, A., & Iranshahi, M. (2013). Zataria multiflora Boiss. (Shirazi thyme) an ancient condiment with modern pharmaceutical uses. Journal of Ethnopharmacology, 145(1), 686-98. [DOI:10.1016/j.jep.2012.12.018] [PMID] [
DOI:10.1016/j.jep.2012.12.018]
29. Saleem, M., Nazli, R., Afza, N., Sami, A., & Ali, M. S. (2004). Biological significance of essential oil of Zataria multiflora Boiss. Journal of Asian Natural Products Research, 18(1), 493-7. [DOI:10.1080/14786410310001608064] [PMID] [
DOI:10.1080/14786410310001608064]
30. Shomali, T., Raeesi, M., & Eskandari-Roozbahani, N. (2016). Zataria multiflora Boiss.essential oil against ethanol-induced gastric ulcer in rats by antioxidant properties and increase in nitric oxide production. Journal of Herbal Medicine Pharmacology, 5(4), 143-8.
31. Wilcock, D. M., Gordon, M. N., & Morgan, D. (2006). Qualification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nature Protocols, 1(4), 1591-5. [DOI:10.1038/nprot.2006.277] [PMID] [
DOI:10.1038/nprot.2006.277]
32. Zussy, C., Brureau, A., Delair, B., Marchal, S., Keller, E., Ixart, G., et al. (2011). Time-course and regional analyses of the physio pathological changes induced after cerebral injection of an amyloid β fragment in rats. The American Journal of Pathology, 179(2), 315-34. [DOI:10.1016/j.ajpath.2011.03.021] [PMID] [PMCID] [
DOI:10.1016/j.ajpath.2011.03.021]